Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Went to the merging company website...nice product
Pammy should get wire fraud charges at the verrry least...IMO
"But your honor..." I could not appear because I was in jail for smoking crank...How could I possibly attend.
BTW Did Pammy get a new investigation by the AG?
The heat is on!
ECGR board stats: Sweet...nearly 100 bookmarks and only 1 ban
Mississippi River Flooding Dooms Farmers
855,750 acres are under water, the worst since 1973
Aprl 28. 2008
AP
REDWOOD, Miss. - Farmers here are experiencing water torture as they wait for the flooded Mississippi River to recede and give them a chance to salvage what's left of what might have been the best season in memory.
Photo: This aerial photograph taken April 16, 2008, near Vicksburg, Miss., shows the extensive nature of the flooding from the Mississippi River, background, and its tributaries. The muddy Mississippi is at levels not seen in more than three decades, putting hundreds of thousands of acres of farmland under water. It's impossible to gauge overall agricultural losses at this point, federal and state officials say, but most agree the tab will be expensive and the damage extensive. (AP)
The muddy Mississippi is at levels not seen in more than three decades, putting hundreds of thousands of acres of farmland under water. It's impossible to gauge overall agricultural losses at this point, federal and state officials say, but most agree the cost will be expensive and the damage extensive.
At Pig Willie's barbecue joint, a cinderblock and cement floor affair attached to a gas station along Highway 61 as the blacktop begins its long, flat run through the Delta, independent farmers recently gathered for lunch and to share their blues.
"Right here in this room it will cost over $1 million," Karsten Simrall said of the difficulties facing farmers. They are wagering potential profits offered by some of the richest soil in the country against the whims of the mercurial Mississippi.
"It'll take us five years to get out of this. It's going to put people out of business," Simrall said. "There's no telling what's going to happen."
Photo: A deserted vehicle along Kings Point Road in western Warren County, near Vicksburg, Miss., is swamped by Yazoo River floodwaters forced over their banks by the backwaters from the Mississippi River, April 17, 2008. The flooding is the worst seen by residents in over three decades. (Rogelio V. Solis / AP)
The river has not reached this level — about 7 feet above flood stage — since 1973.
855,750 ACRES SWAMPED
The U.S. Army Corps of Engineers says a total of 855,750 acres are under either Mississippi floodwater or backwater from the Yazoo River, which drains much of the board-flat Mississippi Delta into the Mississippi River. About 273,000 of those flooded acres are cleared for wheat, cotton, soybeans, corn and other crops.
Simrall recently knocked a hole in a levee his family built more than a century ago to protect their land north of Vicksburg. After failing to keep water out, he feared it will keep in receding floodwaters.
The flood hit just as farmers were preparing to harvest wheat and plant corn, soybeans and cotton. Some, like farmer Brad Bradway, were forced to watch as water crept inch by inch over his 110 acres of wheat until his fields sat under 8 feet of water.
Photo: Farmer Karsten Simrall talks about the difficulties facing farmers as they wait for the flooded Mississippi River to recede, April 17, 2008, at Pig Willie's barbecue joint near Redwood, Miss. "It'll take us five years to get out of this. It's going to put people out of business," Simrall said. "There's no telling what's going to happen." Simrall recently knocked a hole in a levee his family built more than a century ago to protect their land north of Vicksburg. After failing to keep water out, he feared it will now keep receding floodwaters in. (Rogelio V. Solis / AP)
Others are now stuck waiting for the water to recede and the ground to dry before they can plant, guaranteeing a shortened growing season, yield reductions and lower returns. This comes after a drought has left much of the region parched for several years.
"At one point I had 300 acres under water and 240 acres too dry to plant," Bradway said. "What's wrong with this picture?"
Weather is just part of the problem.
Input costs such as fuel and fertilizer have risen dramatically in just a few months. Diesel around Vicksburg costs more than $4 a gallon — or more than $100 per tank for the ubiquitous diesel pickup — and fertilizer that went for $68 an acre last season now runs $100.
Simrall planted 1,700 acres of corn that was about a foot tall when floodwaters covered 1,200 of those acres. He's out $120,000 already and doesn't know if the Mississippi River will recede fast enough for him to salvage that acreage.
He's not alone. The flood has taken not only money farmers invested in the field, but much of the profit they expected. Worse, most sold their crops in advance to take advantage of prices so high few could resist.
Photo: A spray of water hits the camera lens as winds turn a trip across flooded Warren County farm lands near Vicksburg, Miss., into a boat , April 17, 2008. The backwaters from the Mississippi River forced the Yazoo River over its banks and onto thousands of acres of farm land destroying maturing wheat, soybean and corn crops and putting an end to what farmers believed would be a very successful planting season. (Rogelio V. Solis / AP)
Bradway sold 1,000 bushels of winter wheat to a distributor for $7 a bushel. When the flood took his crop, he was still on the hook. So he paid $10.50 a bushel to another distributor for wheat to satisfy his contract. He hopes to turn a profit on soybeans this summer.
LOOKING FOR 'EXIT STRATEGY'
"I'm trying to design an exit strategy because I'm tired of it," Bradway said.
The farmers believe there's a simple solution to the flooding.
The Environmental Protection Agency is threatening to veto the Yazoo Backwater project that would pump excess water out of the Yazoo River wetlands during floods. Critics say the project will hurt the environment and threaten endangered species.
Photo: Hunting camps, farm buildings and residences like this one photographed near Chickasaw Road in Vicksburg, Miss., April 17, 2008, with only its chimney exposed, are now underwater even though many are two-stories high and even on stilts. While the Mississippi River and its backwater tributaries periodically flood adjacent low lying farm lands, farmers, hunters and residents find that even structures built several feet above flood stages, still go underwater. (Rogelio V. Solis / AP)
The veto would break a promise farmers and many area residents believe was made to them when the corps begin to harness the Mississippi with a massive levee system. While the levees keep the river in check, they say much of the benefit is upstream and at their expense.
A corps spokesman says if the Yazoo project were in place, it would have pumped about 4 feet of water off currently flooded land. That would have made quite the difference for Mississippi farmers who work inside the levee system.
Bradway has farmed the same 1,000 acres for three decades. He's had floods big and small in 14 of those 30 years.
This latest, greatest flood cost him $25,000 out of pocket and $45,000 in potential earnings. He wonders if this flood could be the last for Sherman's Defeat Plantation, the site of the Union scourge's only loss during the Civil War.
"I'm trying to keep it from becoming Bradway's Defeat," he said.
Copyright 2008 The Associated Press.
http://www.msnbc.msn.com/id/24351854/
Serious question; if food prices are High...how will BLDV make any money on biodiesel?
I'm taking (BLDV) tomorrow on any pull back..guns blazin
Hey you guys wanna update your Ibox?? Now that it has been determined this is obviously the wrong company....
Hahaa! You the man....thank God because all I see are Class action lawsuits a mile long.
.<font color=green>ENCLAVES GROUP PHONE (914) 592-2100 |
Lets call for updates starting tomorrow as a group
perfect timing as the city council puts this whole plan up for debate....Ask when will ECGR release current news about projects or plans to bring SEC filings current
ECGR's next move will bring SEC filings current...I'm almost sure of it as most bankers will require it.
I'm sure we will have enough video and news press after tomorrow's city council meeting to chew on at least through June.
Get me 1 Pr from the company bag....just one!! I can only imagine....
Looks good in AH..with this small float another day like today and may see $5's
I actually remember this trading in $30+ range two years ago...so I totally understand the hesitancy.
Nevertheless Today's news is huge
1PR bag....that's all we need.
I feel sorry for the folks who sold below .004 on account of YOU KNOW WHO!!
I'm not in jail...I'm here guys!
I saw the great news....still not on yahoo. LOL
NURO NEWS IS REAL: (Here is link...still not on yahoo)
http://phx.corporate-ir.net/phoenix.zhtml?c=180007&p=irol-newsArticle&ID=1135726&highlight=
NeuroMetrix Receives FDA 510(k) Clearance for the ADVANCE(TM) System for the Performance of Nerve Conduction Studies and Needle Electromyography Procedures
WALTHAM, Mass.--(BUSINESS WIRE)--April 28, 2008--NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has received 510(k) clearance for its ADVANCE System ("ADVANCE") from the U.S. Food and Drug Administration (FDA). This regulatory determination by the FDA gives NeuroMetrix clearance to market ADVANCE in the U.S. market. The device is intended to be used by physicians to perform nerve conduction studies and invasive electromyography procedures.
ADVANCE is a comprehensive platform for the performance of traditional nerve conduction studies and invasive electromyography procedures. The technical specifications include a precision electrical stimulator and dual recording channels for acquiring nerve conduction responses. A third channel is available for recording needle electromyography signals. ADVANCE introduces several important technological improvements into the market. These include a small form factor and power from a high capacity lithium-ion battery making use of the device convenient in many environments. The amplification and digitization hardware is embedded in the cable connector thereby providing digital signal transmission from the recording electrodes to the device. This technology reduces susceptibility to electrical interference and makes the device suitable for all settings, even challenging applications such as nerve function assessment in intensive care units. The device is designed around a high-resolution color touch screen that facilitates real-time review and editing of nerve conduction waveforms. Integrated Bluetooth(R) provides convenient wireless communication with data management and report generation servers. This wireless link also enables expansion of system capabilities with the introduction of modules in the future. Finally, several enhancements have been made to the proprietary NeuroMetrix neurophysiological analysis software, which is resident on ADVANCE devices. We believe that this software provides physicians with accurate, reliable, and clinically useful nerve conduction parameters.
"ADVANCE builds on our extensive experience developing, manufacturing, and marketing neurophysiological technologies," said Shai N. Gozani, M.D., Ph.D., NeuroMetrix's President and Chief Executive Officer. "Our NC-stat device has been on the market since 1999 with over 1.0 million patients tested since its introduction. The NC-stat has also been used in multiple large-scale federally funded epidemiological studies and as part of Phase I and successful Phase III drug registration trials that were reviewed by the FDA, including Lilly & Co's Duloxetine HCl (Cymbalta(R)). Although ADVANCE leverages our experience with the NC-stat, it is a new and distinct product platform. The primary regulatory predicate for ADVANCE is the Keypoint(R) device originally manufactured and marketed by Medtronic, Inc. to neurologists and physical medicine and rehabilitation ("PM&R") physicians for the performance of traditional nerve conduction studies and invasive electromyography procedures."
Dr. Gozani continued, "We expect to continue marketing the NC-stat in those markets for which its straightforward operation, proven accuracy and reliability, and automated reports are viewed as key product features. These include a portion of primary care physicians, industrial pre-placement and wellness programs, clinical studies and research, and certain international markets. In contrast to the NC-stat, ADVANCE is a traditional system that supports nerve conduction testing with any electrode methodology, real-time waveform review and cursor editing, invasive electromyography procedures, and traditional reports. We anticipate marketing ADVANCE to specialists, including neurologists, PM&R physicians, neurosurgeons, hand and plastic surgeons, and other specialists who intend to perform traditional nerve conduction studies and invasive electromyography procedures. We believe that the technological and clinical features of ADVANCE, its overall cost, and the exceptional customer and technical support provided by NeuroMetrix will be attractive compared to the other devices in this market segment."
"Finally, consistent with the broad functionality supported by ADVANCE, we are in the process of expanding our consumables offerings with the addition of new lines of disposable electrodes and single use concentric electromyography needles," concluded Dr. Gozani.
About NeuroMetrix
NeuroMetrix is a science based medical device company advancing patient care through the development and marketing of innovative medical device products that aid physicians in the diagnosis and treatment of diseases of the nervous system and neurovascular disorders, and that provide regional anesthesia and pain control. To date, our focus has been on the assessment of neuropathies and neurovascular disorders. Neuropathies affect the peripheral nerves and parts of the spine and are frequently caused by or associated with carpal tunnel syndrome, diabetes, and low back and leg pain, as well as other clinical disorders. The NC-stat System, NeuroMetrix's initial neuropathy evaluation system, has been on the market since May 1999 and is used in over 5,500 physician's offices and clinics in the United States for performance of nerve conduction studies. The ADVANCE System, recently cleared by the FDA for marketing in the U.S., is a system for the performance of traditional nerve conduction studies and invasive electromyography procedures.
Diabetic retinopathy is a common neurovascular complication of diabetes and the leading cause of blindness among working age adults. Through the acquisition of EyeTel Imaging, NeuroMetrix markets the DigiScope(TM), which is a retinal imaging system designed for use at the point-of-care in physician offices and vision clinics.
Our product pipeline includes the NAVIGATOR(TM) System, a device designed to precisely deliver pharmacologic agents such as anesthetics and corticosteroids in close proximity to nerves ("perineurally") for regional anesthesia, pain control and the treatment of focal neuropathies such as carpal tunnel syndrome. We are also developing a neurostimulation based product that promotes nerve fiber regeneration for the treatment of acute nerve injuries such as due to lacerations and other forms of trauma.
The statements contained in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding NeuroMetrix's or its management's expectations, hopes, beliefs, intentions or strategies regarding the future. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "plan," "hope" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this press release are based on NeuroMetrix's current expectations and beliefs concerning future developments and their potential effects on it. There can be no assurance that future developments affecting NeuroMetrix will be those that NeuroMetrix has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond NeuroMetrix's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with: reimbursement by third party payers to the Company's customers for procedures performed using ADVANCE; our success in marketing ADVANCE; the effectiveness of the Company's or its collaborators' products compared to other medical device products; potential future publication of articles or announcement of positions by physician associations or other organizations that are unfavorable to the Company's or its collaborators' products; plus factors described under the heading "Item 1A. Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2007 or described in the Company's other public filings.
Should one or more of these risks or uncertainties materialize, or should any of NeuroMetrix's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. NeuroMetrix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
CONTACT: NeuroMetrix, Inc.
Bradford Smith, 781-314-2741
Chief Financial Officer
neurometrix.ir@neurometrix.com
SOURCE: NeuroMetrix, Inc. NeuroMetrix, Inc.
Copyright © 2008 NeuroMetrix, Inc. All rights reserved. Privacy Statement NEUROMetrix®, NC-stat®, and onCall™ are trademarks of NEUROMetrix, Inc. Content on this site is not intended as a substitute for medical advice. You may not copy, republish, redistribute or commercially utilize in any manner any of these materials without prior written permission from NeuroMetrix, Inc.
NURO NEWS IS REAL: (Here is link...still not on yahoo)
http://phx.corporate-ir.net/phoenix.zhtml?c=180007&p=irol-newsArticle&ID=1135726&highlight=
NeuroMetrix Receives FDA 510(k) Clearance for the ADVANCE(TM) System for the Performance of Nerve Conduction Studies and Needle Electromyography Procedures
WALTHAM, Mass.--(BUSINESS WIRE)--April 28, 2008--NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has received 510(k) clearance for its ADVANCE System ("ADVANCE") from the U.S. Food and Drug Administration (FDA). This regulatory determination by the FDA gives NeuroMetrix clearance to market ADVANCE in the U.S. market. The device is intended to be used by physicians to perform nerve conduction studies and invasive electromyography procedures.
ADVANCE is a comprehensive platform for the performance of traditional nerve conduction studies and invasive electromyography procedures. The technical specifications include a precision electrical stimulator and dual recording channels for acquiring nerve conduction responses. A third channel is available for recording needle electromyography signals. ADVANCE introduces several important technological improvements into the market. These include a small form factor and power from a high capacity lithium-ion battery making use of the device convenient in many environments. The amplification and digitization hardware is embedded in the cable connector thereby providing digital signal transmission from the recording electrodes to the device. This technology reduces susceptibility to electrical interference and makes the device suitable for all settings, even challenging applications such as nerve function assessment in intensive care units. The device is designed around a high-resolution color touch screen that facilitates real-time review and editing of nerve conduction waveforms. Integrated Bluetooth(R) provides convenient wireless communication with data management and report generation servers. This wireless link also enables expansion of system capabilities with the introduction of modules in the future. Finally, several enhancements have been made to the proprietary NeuroMetrix neurophysiological analysis software, which is resident on ADVANCE devices. We believe that this software provides physicians with accurate, reliable, and clinically useful nerve conduction parameters.
"ADVANCE builds on our extensive experience developing, manufacturing, and marketing neurophysiological technologies," said Shai N. Gozani, M.D., Ph.D., NeuroMetrix's President and Chief Executive Officer. "Our NC-stat device has been on the market since 1999 with over 1.0 million patients tested since its introduction. The NC-stat has also been used in multiple large-scale federally funded epidemiological studies and as part of Phase I and successful Phase III drug registration trials that were reviewed by the FDA, including Lilly & Co's Duloxetine HCl (Cymbalta(R)). Although ADVANCE leverages our experience with the NC-stat, it is a new and distinct product platform. The primary regulatory predicate for ADVANCE is the Keypoint(R) device originally manufactured and marketed by Medtronic, Inc. to neurologists and physical medicine and rehabilitation ("PM&R") physicians for the performance of traditional nerve conduction studies and invasive electromyography procedures."
Dr. Gozani continued, "We expect to continue marketing the NC-stat in those markets for which its straightforward operation, proven accuracy and reliability, and automated reports are viewed as key product features. These include a portion of primary care physicians, industrial pre-placement and wellness programs, clinical studies and research, and certain international markets. In contrast to the NC-stat, ADVANCE is a traditional system that supports nerve conduction testing with any electrode methodology, real-time waveform review and cursor editing, invasive electromyography procedures, and traditional reports. We anticipate marketing ADVANCE to specialists, including neurologists, PM&R physicians, neurosurgeons, hand and plastic surgeons, and other specialists who intend to perform traditional nerve conduction studies and invasive electromyography procedures. We believe that the technological and clinical features of ADVANCE, its overall cost, and the exceptional customer and technical support provided by NeuroMetrix will be attractive compared to the other devices in this market segment."
"Finally, consistent with the broad functionality supported by ADVANCE, we are in the process of expanding our consumables offerings with the addition of new lines of disposable electrodes and single use concentric electromyography needles," concluded Dr. Gozani.
About NeuroMetrix
NeuroMetrix is a science based medical device company advancing patient care through the development and marketing of innovative medical device products that aid physicians in the diagnosis and treatment of diseases of the nervous system and neurovascular disorders, and that provide regional anesthesia and pain control. To date, our focus has been on the assessment of neuropathies and neurovascular disorders. Neuropathies affect the peripheral nerves and parts of the spine and are frequently caused by or associated with carpal tunnel syndrome, diabetes, and low back and leg pain, as well as other clinical disorders. The NC-stat System, NeuroMetrix's initial neuropathy evaluation system, has been on the market since May 1999 and is used in over 5,500 physician's offices and clinics in the United States for performance of nerve conduction studies. The ADVANCE System, recently cleared by the FDA for marketing in the U.S., is a system for the performance of traditional nerve conduction studies and invasive electromyography procedures.
Diabetic retinopathy is a common neurovascular complication of diabetes and the leading cause of blindness among working age adults. Through the acquisition of EyeTel Imaging, NeuroMetrix markets the DigiScope(TM), which is a retinal imaging system designed for use at the point-of-care in physician offices and vision clinics.
Our product pipeline includes the NAVIGATOR(TM) System, a device designed to precisely deliver pharmacologic agents such as anesthetics and corticosteroids in close proximity to nerves ("perineurally") for regional anesthesia, pain control and the treatment of focal neuropathies such as carpal tunnel syndrome. We are also developing a neurostimulation based product that promotes nerve fiber regeneration for the treatment of acute nerve injuries such as due to lacerations and other forms of trauma.
The statements contained in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding NeuroMetrix's or its management's expectations, hopes, beliefs, intentions or strategies regarding the future. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "plan," "hope" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this press release are based on NeuroMetrix's current expectations and beliefs concerning future developments and their potential effects on it. There can be no assurance that future developments affecting NeuroMetrix will be those that NeuroMetrix has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond NeuroMetrix's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with: reimbursement by third party payers to the Company's customers for procedures performed using ADVANCE; our success in marketing ADVANCE; the effectiveness of the Company's or its collaborators' products compared to other medical device products; potential future publication of articles or announcement of positions by physician associations or other organizations that are unfavorable to the Company's or its collaborators' products; plus factors described under the heading "Item 1A. Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2007 or described in the Company's other public filings.
Should one or more of these risks or uncertainties materialize, or should any of NeuroMetrix's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. NeuroMetrix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
CONTACT: NeuroMetrix, Inc.
Bradford Smith, 781-314-2741
Chief Financial Officer
neurometrix.ir@neurometrix.com
SOURCE: NeuroMetrix, Inc. NeuroMetrix, Inc.
Copyright © 2008 NeuroMetrix, Inc. All rights reserved. Privacy Statement NEUROMetrix®, NC-stat®, and onCall™ are trademarks of NEUROMetrix, Inc. Content on this site is not intended as a substitute for medical advice. You may not copy, republish, redistribute or commercially utilize in any manner any of these materials without prior written permission from NeuroMetrix, Inc.
NURO...Weird? Yahoo did not post the news????
WALTHAM, Mass.--(BUSINESS WIRE)--April 28, 2008--NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has received 510(k) clearance for its ADVANCE System ("ADVANCE") from the U.S. Food and Drug Administration (FDA). This regulatory determination by the FDA gives NeuroMetrix clearance to market ADVANCE in the U.S. market. The device is intended to be used by physicians to perform nerve conduction studies and invasive electromyography procedures.
I'm a moderator here...so how come I can't edit the ibox????
Great...so this is just a shell? "Bio Tec is calling themselves Bio Tec Fuels and Chemicals LLC"
Something does not jive
This is verrrrrry thin
Running like a fat kid behind a bike...
did bashers oversleep
Looks like it's in Carrolton too...gee where have I heard Carrolton Texas?
http://www.google.com/search?hl=en&q=homes+of+azalea+park&btnG=Google+Search
Dude... Is this a another HFA property: http://dittodoesit.com/identity-design/homes-for-america-holdings.html
Nothing fancy but it sure looks like HFA's
Things are moving now brother...City council meeting tomorrow to discuss the overall phase of projects and lookey HFA posted news in March...I completely missed it!!! LOL
Some things are right under your nose (wink!)
Cheers!
Oh my....HFA posted news in March how could I have missed it:
http://pointstreetlanding.com/pointstreetlandingnews.htm
Looks like they do care
Why would Rico reduce the 2b auth when he increased it to begin with???
I find it amazing a CEO of a public company doesn't have a bio of himself....
When is the CEO's bio going to be posted. Thanks
Good Morning all$$$ Let's break the 1c wall to bits!
Does Alex have a bios online....Thanks
USA Financial...HFA's former lender is in bankruptcy. Big deal... How does this affect ECGR????
Is USA financial one of ECGR's lenders too....I don't know where you are coming from.
Make the ECGR-USA financial connection or the posts will be deleted.
Once again...show me "ANY" connection between HFA's former bank lender and the Enclave group.